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Abstract: The prognosis of patients with chronic heart failure (CHF) still remains poor, despite 
the recent advances in medical and surgical treatment. Furthermore, CHF is a major public health 
problem in most industrialized countries where the elderly population is rapidly increasing. 
Although the prevalence and mortality of CHF used to be relatively low in Japan, the disorder has 
been markedly increasing due to the rapid aging of the society and the Westernization of lifestyle 
that facilitates the development of coronary artery disease. The Chronic Heart Failure Analysis 
and Registry in the Tohoku District (CHART)-1 study was one of the largest cohorts in Japan. The 
study has clariﬁ  ed the characteristics and prognosis of Japanese patients with CHF, demonstrating 
that their prognosis was similarly poor compared with those in Western countries. However, we 
still need evidence for the prevention and treatment of CHF based on the large cohort studies or 
randomized treatment trials in the Japanese population. Since the strategy for CHF management is 
now changing from treatment to prevention, a larger-size prospective cohort, called the CHART-2 
study, has been initiated to evaluate the risk factors of CHF in Japan. This review summarizes the 
current status of CHF studies in Japan and discusses their future perspectives.
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Introduction
Chronic heart failure (CHF) is the leading cause of mortality in most developed 
countries (Hunt et al 2001). The prevalence and mortality rates of CHF used to be 
relatively lower in Japan compared with other Western countries. In Japan, approxi-
mately 1 to 2 million patients have CHF and nearly 170,000 patients die due to heart 
diseases each year (approximately 130 per 100,000 person-years) (Summary of Vital 
Statistics 2005). However, the prevalence and death rates of cardiovascular diseases 
and CHF have been rapidly increasing in Japan, due to the Westernization of lifestyle, 
including dietary habits, and the aging population (The Status of Aging 2007). The 
Chronic Heart Failure Analysis and Registry in the Tohoku District (CHART)-1 study 
was one of the largest cohort studies with Japanese CHF patients (N = 1,278), which 
was designed to evaluate the characteristics and prognosis of those patients. We have 
also started a new cohort study, named the CHART-2 study (N = 10,000, expected) 
aiming to elucidate the effective preventive measures for CHF. This review brieﬂ  y 
summarizes the major socio-medical issues of Japanese patients with CHF, their 
clinical characteristics and prognosis found in our CHART-1 study, and the current 
status of CHF studies in Japan.
Socio-medical status of Japanese
patients with CHF
Rapid aging of Japanese population
Until the 1980s, Japan had a lower percentage of elderly citizens compared with any 
other developed countries. However Japan is now one of the countries in which the Vascular Health and Risk Management 2008:4(1) 104
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population is aging rapidly. Figure 1 shows the time-course 
of aging and population projections between 1950 and 2055, 
which is assembled using the data reported by the Japanese 
Cabinet Ofﬁ  ce (The Status of Aging 2007). As of October 
1, 2006, the total population of Japan was 127.8 million and 
the number of elderly aged 65 or older was 26.6 million, 
accounting for 21% of the total population. The elderly 
population is expected to continue to increase rapidly and 
the percentage of the elderly will reach 35.8 million (27%) in 
2055 (The Status of Aging 2007). Life expectancy in Japan 
at birth has also drastically increased since World War II to 
78.6 years for males and 85.5 years for females in 2005 (Life 
Expectancies at Speciﬁ  ed Ages 2006). The Japanese Cabinet 
Ofﬁ  ce expects that it will reach 83.7 years for males and 90.3 
years for female in 2055. Thus, in the near future, Japanese 
society will encounter more difﬁ  cult medical problems due 
to rapid aging, which other developed countries have never 
before experienced.
Changing causes of death in Japan
Infectious diseases such as pneumonia, tuberculosis, and 
gastroenteritis were the leading causes of death in Japan until 
the mid 1900s. The major health problems in Japanese society 
have drastically changed since World War II. The morbid-
ity and mortality rates of lifestyle-related diseases such as 
cancer, heart disease, stroke, and diabetes mellitus have 
dramatically increased. Approximately 60% of the mortality 
is now attributed to lifestyle-related diseases (cancer, 31%; 
ischemic heart disease 16%; cerebrovascular disease 13%; 
diabetes mellitus 1%; and hypertensive disease 0.6%) and 
the medical costs for these diseases amounts to 10.2 trillion 
yen (87.8 billion US dollars), accounting for approximately 
30% of the total cost of the Japanese health insurance in 
2003 (Exercise and Physical Activity Reference for Health 
Promotion 2006). Currently, heart disease is the second most 
frequent cause of death in Japan. Figure 1 shows the trend 
of the mortality due to heart diseases, which is constructed 
using the reports of death certiﬁ  cates in Japan (Summary of 
Vital Statistics 2005). There is a clear trend for the increase 
in death due to heart disease since 1950s (there was a tem-
porary sharp decline in 1995 due to the tenth revision of 
the International Classiﬁ  cation of Diseases regarding the 
description of diagnosis in death certiﬁ  cates).
Health insurance system and future 
economic burden in Japan
In Japan, all citizens are enrolled in the mandatory health 
insurance system based on employment and residential status. 
The average number of visits to a doctor per year is 16 in 
Japan, versus 5.8 visits in the United States (Itoh 2004). As 
elderly patients tend to visit doctors more frequently and to 
have more medication or high-cost medical care, medical 
Figure 1 Time-course and future prediction of the increase in elderly population and heart-disease mortality in Japan. Data are based on the Status of Aging and Implemen-
tation of Measures for Aging Society in 2005, reported by the Japanese Cabinet.Vascular Health and Risk Management 2008:4(1) 105
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expenditure for the elderly is already taking one-third of the 
national health expenditure, and is projected to reach a half 
of the expenditure by the year 2025 (Itoh 2004). Progressive 
aging of the society and the consequent increase in the num-
ber of patients with CHF will cause more ﬁ  nancial burden 
within Japanese society, which could lower the quality of 
medical services in the future.
An overview of heart failure
studies in Japan
In Japan, medical treatment for patients with CHF is mainly 
based on the evidence obtained from randomized trials in 
the United States and Europe. There have been no sufﬁ  cient 
randomized treatment trials or prospective cohort studies in 
Japan to clarify the real characteristics of Japanese patients 
with CHF or to improve their prognosis and quality of life. 
The mandatory health insurance system, the shortage of 
the budget to fulﬁ  ll mega-trials, and the absence of trained 
research nurse system may all be responsible for the current 
situation. This section describes several cohort studies with 
Japanese CHF patients, major outcomes of the CHART-1 
study, and randomized treatment trials for CHF performed 
with Japanese patients, either those that have already been 
published or are currently in progress. Finally, racial differ-
ences will be discussed, because this issue may also inﬂ  uence 
the impact of risk factors and/or the effects of treatments 
for CHF.
Prospective cohort studies in Japan
There are few multi-institutional prospective cohort studies 
with CHF patients in Japan (Table 1). The Chronic Heart Fail-
ure Analysis and Registry in the Tohoku District (CHART)-1 
study was the ﬁ  rst cohort study in Japan, including more than 
1,000 Japanese patients with stable CHF, who were registered 
at 26 hospitals in the Tohoku district with a population of 
approximately 9.8 million (Shiba et al 2004). The CHART-1 
study was initiated in February 2000 and was completed in 
December 2005. The total number of CHF patients enrolled 
was 1,278 and the mean follow-up period was 3.5 years. 
Details of design and the main outcome will be presented 
at the following part in this article. The Japanese Cardiac 
Registry of Heart Failure in Cardiology (JCARE-CARD) is 
a registry of hospitalized patients with worsening CHF at 164 
hospitals throughout the country between January 2004 and 
June 2005 (Tsutsui et al 2006). Death and hospital admission 
of the patients were followed through 2006 with the mean 
follow-up period of at least 1 year. Results of this study will 
appear in the near future. The Japanese Cardiac Registry of 
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Heart Failure in General Practice (JCARE-GENERAL) is a 
registry of outpatients with CHF managed by cardiologists 
in hospitals and primary care physicians in general practice 
(Tsutsui et al 2007). Baseline data of totally 2,685 patients 
were collected during November 2004 and follow-up data 
were collected for 1 year after the enrolment. During the 
mean follow-up period of 427 days, the crude mortality 
rate was 6.7% in patients managed by cardiologists and 
5.9% in those managed by general physicians. The Chronic 
Heart Failure Analysis and Registry in the Tohoku District 
(CHART)-2 study is currently the largest prospective and 
hospital-based cohort study with patients with CHF in Japan. 
This study was designed to investigate the characteristics 
and prognosis of a total of 10,000 patients with symptomatic 
CHF (Stage C/D in the ACC/AHA classiﬁ  cation) and those 
with structural heart disease but without signs or symptoms 
of CHF (Stage-B in the AHA/ACC classiﬁ  cation) (Hunt et al 
2001). This study will elucidate the incidence and prognostic 
impact of metabolic syndrome in those patients, especially 
on the development of the ﬁ  rst symptomatic CHF. The 
CHART-2 study was started in October 2006 and will be 
completed in September 2011.
The CHART -1 Study
Risk stratiﬁ  cation is the ﬁ  rst line strategy to improve the 
prognosis and quality of life of patients with CHF. A number 
of factors have been found to correlate with the mortality 
of patients with CHF (Rector et al 1994; Deedwania 2003; 
Bettencourt et al 2000). The CHART-1 study was started to 
register patients with stable CHF in February 2000 to clarify 
the characteristics and prognosis and to seek for prognostic 
factors in Japanese CHF patients (Shiba et al 2004, 2005). 
Patients were enrolled when at least one of the following 
criteria was met: (1) left ventricular ejection fraction (LVEF) 
 50%, (2) left ventricular end-diastolic dimension  55 mm, 
or (3) at least one episode of congestive heart failure. Patients 
less than 18 years old or those with clinically unstable condi-
tions were excluded. Baseline data, including laboratory ﬁ  nd-
ings, results of echocardiography, and medical treatments for 
CHF, were recorded and annual surveillance was performed 
until the end of 2005.
Characteristics and prognosis of patients 
with CHF in Japan.
A total of 1,278 patients were enrolled in the CHART-1 
cohort. The mean age of the study population was 68.3 years, 
and male accounted for 66% of the total study population. 
The prevalence of diabetes mellitus and hypertension was 
19% and 47%, respectively. Other baseline characteristics of 
patients are shown in Table 2. Ischemic etiology accounted 
for only 25% and the percentage of patients older than 
65 years was 66%. Patients with preserved systolic function 
(deﬁ  ned as LVEF  50%) accounted for 45% of the total 
population. During the mean follow-up period of 3.5 years, 
all-cause mortality rate at 1-, 2-, and 3-year was 7%, 16%, 
and 22%, respectively (Figure 2). Multivariate Cox analysis 
showed that several covariates, such as age, diabetes mellitus, 
ventricular tachycardia, serum level of B-type natriuretic pep-
tide (BNP), rural residence, and NYHA functional class, were 
signiﬁ  cantly associated with all-cause mortality (Shiba et al 
2004). Figure 3 shows the Kaplan-Meier analyses of freedom 
from all-cause mortality in patients stratiﬁ  ed by serum level 
of BNP or LVEF. Patients with higher BNP concentration 
had a signiﬁ  cantly poorer prognosis (Watanabe et al 2005), 
however, the prognostic impact was not signiﬁ  cantly differ-
ent between patients with 200–500 pg/mL of BNP level and 
those with  500 pg/mL (Figure 3A). The all-cause mortality 
of patients with preserved systolic function (LVEF   50%) 
was not signiﬁ  cantly different than that of patients with 
Table 2 Baseline characteristics of the Japanese patients in the 
CHART-1 study
No. of patients  1,278
Follow-up period (years)  3.5 ± 1.7
Age (years)  68.3 ± 13.4
   39 3.7%
 40–64  30.2%
 65–74  32.8%
   75 33.3%
Male (%)  66.0%
NYHA
 I  19.7%
 II  63.0%
 III  16.5%
 IV  0.8%
Underlying disease
  Coronary artery disease  25.4%
  Valvular heart disease  26.4%
  Left ventricular hypertrophy  14.0%
 Non-ischemic  cardiomyopathy  28.6%
 Other  5.6%
Left ventricular ejection fraction (%)  51.1 ± 15.9
   30% 11.7%
 30–50%  43.7%
   50% 44.6%
Hypertension 47.4%
Diabetes 18.9%
Dyslipidemia 16.7%
Atrial ﬁ  brillation  41.8%
Ventricular tachycardia  20.1%
History of heart failure admission  23.4%
Abbreviations: NYHA, New York Heart Association.Vascular Health and Risk Management 2008:4(1) 107
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moderately decreased LVEF (30%–50%). However the 
prognosis of those with severely low LVEF ( 30%) was 
the lowest with frequent episodes of sudden cardiac death 
(Figure 3B). The 3-year incidence of sudden death was higher 
in patients with LVEF  30% than those with LVEF  30% 
(15% vs 4%, respectively, p   0.001). Primary prevention of 
sudden cardiac death with an implantable cardioverter deﬁ  -
brillator in those patients should be recommended when they 
meet the criteria in the authorized guidelines (Watanabe et al 
2006). Recently, anemia has been emphasized as an important 
prognostic predictor in patients with CHF (Ezekowitz et al 
2003). Our data also showed that anemia was signiﬁ  cantly 
associated with all-cause mortality, cardiac-cause mortality, 
and sudden death in patients with diastolic CHF (Tada et al 
2007), as well as in those with systolic CHF, as reported by 
other researchers (O’Meara et al 2006).
Treatment of patients with CHF
in Japan
Treatments with angiotensin converting enzyme inhibitors 
(ACEI), angiotensin II receptor blockers (ARB), or β-blockers 
are recommended to improve prognosis and quality of life 
for patients with CHF (Hunt et al 2001). However it has 
previously been reported that such evidence-based treatments 
might not be sufﬁ  ciently used in patients who should have 
had beneﬁ  ts of such medications (Masoudi et al 2003). The 
overall usage rate of ACEI/ARB or β-blocker in patients 
enrolled in the CHART-1 study was 70% and 28%, respec-
tively (Figure 4). The penetration rate of these medications 
was relatively lower in female patients, elderly patients, and 
those with valvular heart disease or preserved LVEF, and 
this trend was more evident for the treatment with β-blocker 
than ACEI/ARB (Figure 4). These results suggest that future 
clinical trials are still necessary for such minorities who have 
not usually been enrolled in major randomized treatment 
trials for CHF.
Clinical outcomes of Japanese
patients with CHF
Figure 5 showed survival curves of placebo groups in ran-
domized treatment trials for CHF performed in Western 
countries, superimposed with the result obtained in our 
CHART-1 study with Japanese CHF patients. One-year all-
cause mortality of patients with mild-moderate CHF (NYHA 
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Figure 3 Kaplan-Meier curves of freedom from all-cause death stratiﬁ  ed by (A) BNP 
and (B) LVEF in the CHART-1 study.
Abbreviations: BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction.
Figure 2 Prognosis of the Japanese patients with CHF in the CHART-1 study. Copy-
right © 2004. Reproduced with permission from Shiba N, Watanabe J, Shinozaki T, 
et al. 2004. Analysis of chronic heart failure registry in the Tohoku district: third year 
follow-up. Circ J, 68:427–34.
Abbreviations: HF, heart failure.Vascular Health and Risk Management 2008:4(1) 108
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II–IV and LVEF  40%) or moderate-severe CHF (NYHA 
III–IV and LVEF  35%) was 13% and 21%, respectively. 
Importantly, as is evident in Figure 5, the prognosis of 
Japanese patients with CHF was equally poor compared with 
Western CHF patients. Since the Japanese society is aging 
rapidly, a sharp increase in the number of CHF patients will 
be inevitable in the near future in Japan, as CHF is a disease 
of the elderly. Figure 6 shows the event rate in CHF patients 
based on age at the entry, demonstrating that elderly Japanese 
patients with CHF had an increased incidence of cardiac 
death and a combination of cardiac death and admission due 
to congestive CHF. This is because elderly CHF patients 
have a higher rate of combined risk factors, such as anemia, 
chronic kidney disease, hypertension, and atrial ﬁ  brillation. 
Appropriate prevention strategies against the development 
and progression of CHF should be undertaken in Japan.
Major CHF treatment trials in Japan
There are 2 published randomized treatment trials for CHF 
patients in Japan (Table 3). The Multicenter Carvedilol 
Heart Failure Dose Assessment (MUCHA) trial enrolled 174 
patients with mild to moderate CHF to seek for the efﬁ  cacy 
and optimum dose of carvedilol, with 3 treatment arms, 
including placebo, 5 and 20 mg of the β-blocker in daily dose 
(Hori et al 2004). During the 24–48 weeks of the treatment 
period, carvedilol achieved dose-related improvement of the 
rate of death or cardiovascular hospitalization to 25%, 9%, 
and 5% in the placebo, 5 mg, and 20 mg group, respectively 
(p = 0.002). The Assessment of Response to Candesartan 
in Heart Failure in Japan (ARCH-J) study investigated the 
efﬁ  cacy of candesartan (8 mg once daily) in comparison 
with the placebo in 305 patients with symptomatic CHF 
(Matsumori et al 2003). During the 6-month follow-up 
period, fatal cardiovascular events occurred in 2 patients in 
each treatment group and the incidence of progression of 
CHF was 7% and 22% in the candesartan and the placebo 
group, respectively (p = 0.0004).
We have recently initiated a large outcome study with 
olmesartan in CHF patients, termed The Supplemental 
Beneﬁ  t of Angiotensin II Receptor Blocker in Hypertensive 
Figure 4 Prevalence of the use of renin-angiotensin inhibitors and β-blockers in the CHART-1 study. Copyright © 2007. Reproduced with permission from Shiba N, Takahashi 
J, Matsuki M. 2007. The CHART Study (Japanese). Naika, 99:410–14.
Abbreviations: ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; NICM, non-ischemic cardiomyopathy; 
LVH, left ventricular hypertrophy; VHD, valvular heart disease.Vascular Health and Risk Management 2008:4(1) 109
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Figure 5 Comparison of the prognosis of patients with CHF between Western clinical trials and the CHART-1 study. Copyright © 2007. Reproduced with permission from 
Shiba N, Takahashi J, Matsuki M. 2007. The CHART Study (Japanese). Naika, 99:410–14.
Abbreviations: HYHA, New York Heart Association.
Figure 6 Prognosis of elderly patients with CHF in the CHART-1 study. Copyright © 2007. Reproduced with permission from Shiba N, Takahashi J, Matsuki M. 2007. The 
CHART Study (Japanese). Naika, 99:410–14.
Abbreviations: CHF, congestive heart failure.
Patients with Stable Heart Failure Using Olmesartan 
(SUPPORT trial), which is currently the largest outcome 
study in Japan (Table 3). The purpose of our SUPPORT 
trial is to examine whether an ARB, olmesartan, in addi-
tion to conventional treatment, reduces the mortality and 
morbidity of hypertensive patients with stable CHF. The 
primary endpoint is a combined event of all-cause death, 
nonfatal acute myocardial infarction, nonfatal stroke, and 
hospital admission due to congestive heart failure. We also 
aim to evaluate the beneﬁ  cial effect of olmesartan on the Vascular Health and Risk Management 2008:4(1) 110
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progression of metabolic syndrome. The entry of patients 
was started in November 2007, and the results of the study 
will be obtained by the end of 2011.
There are 5 other small outcome trials that are currently 
in progress in Japan (Table 3). The Assessment of Beta-
Blocker Treatment in Japanese Patients with Chronic Heart 
Failure (J-CHF) and the Japanese Diastolic Heart Failure 
Study (J-DHF) are investigating the effects of carvedilol in 
patients with systolic CHF and those with diastolic CHF, 
respectively. Another objective of J-CHF is to determine 
the optimum dose of carvedilol and to elucidate the dif-
ferences in clinical characteristics between responders 
and nonresponders to the β-blocker. The Pitavastatin 
Heart Failure Study (PEARL study) is designed to evalu-
ate the efﬁ  cacy of pitavastatin for CHF with mild hyper-
cholesterolemia. The Japanese Multicenter Evaluation of 
Long- versus short-acting Diuretics in Congestive Heart 
Failure (J-MELODIC) is designed to compare the effects 
of furosemide and azosemide in patients with CHF and to 
test the hypothesis that long-acting diuretics are superior 
to short-acting ones in those patients. The Japanese Heart 
Failure Outpatients Disease Management and Cardiac 
Evaluation Study (J-HOMECARE) was designed to evalu-
ate the beneﬁ  t of disease management program for prog-
nosis, psychological status and quality of life of patients 
with CHF.
There are 2 large trials that have investigated the role of 
valsartan in Japanese patients with cardiovascular disease 
including CHF (Table 4). The Japanese Investigation of 
Kinetic Evaluation in Hypertensive Event and Remodeling 
Treatment (JIKEI-HEART) Study was designed to investi-
gate whether concomitant treatment with valsartan in addition 
to conventional treatment improves the prognosis of Japanese 
patients with hypertension, ischemic heart disease, or con-
gestive heart failure. The results of this study have recently 
been published (Mochizuki et al 2007). After a median fol-
low-up period of 3.1 years, the incidences of stroke, transient 
ischemic attack, angina pectoris, and CHF were signiﬁ  cantly 
lower in patients treated with valsartan compared with those 
with the conventional treatment. However, the beneﬁ  t of the 
add-on valsartan treatment in a sub-population with CHF, 
which accounted for 11% of the total population, has not been 
published yet. The Add-on Effects of Valsartan on Morbi-
Mortality (KYOTO-HEART) study was designed to assess 
the add-on effect of valsartan on the conventional treatment 
in terms of the morbidity and mortality in Japanese hyper-
tensive patients with high risks of cardiovascular diseases 
including CHF (Table 4).
Many of the randomized clinical trials performed in 
Japan utilize the prospective randomized open blinded end-
point (PROBE) design, as an alternative to the randomized 
double-blind placebo-controlled design (Tables 3 and 4). 
This is mainly because the PROBE study tends to be more 
cost effective and its open-labeled medication may minimize 
ethical considerations (Hansson et al 1992).
Racial difference in morbidity and mortality 
due to cardiovascular diseases
Several researchers have suggested that cardiovascular risk 
factors have different prognostic impact among different 
populations. The Seven Countries Study Research Group 
showed a substantial heterogeneity among populations in 
terms of the death rate due to coronary artery disease, even 
at a similar level of blood pressure (Van den Hoogen et al 
2000). The proportion of deaths attributable to cardiovascu-
lar disease has also been reported to vary among different 
cohorts even at the similar serum cholesterol level. The long-
term follow-up for 25 years for 12,763 men in 16 cohorts 
in Europe, the United States, and Japan showed that the 
risk factors of cardiovascular disease, such as insufﬁ  cient 
physical activity and high serum cholesterol level, were 
not signiﬁ  cantly associated with all-cause death in several 
countries including Japan (Menotti et al 2001). Since these 
differences cannot be explained by other baseline character-
istics, smoking habits, or genetic difference, environmental 
and/or behavioral factors may play an important role in the 
development of cardiovascular diseases. The Ni-Hon-San 
Study, which compared cardiovascular disease rates and 
risk factors in Japanese men living in Japan, Hawaii, and 
California, showed that the mortality rate due to coronary 
artery disease was lowest in Japanese men living in Japan, 
whereas it was highest in those living in California (Benfante 
1992). Racial differences may also inﬂ  uence the effect of 
medical treatment for CHF. Several studies demonstrated that 
genetic polymorphisms and/or a difference in β1-receptor 
sensitivity, which are frequently observed in the Japanese 
population, might change the pharmacokinetics or the clini-
cal effect of medical drugs, such as ACEI and β-blockers 
(Kubota et al 2000; Xie et al 2001; Ranade et al 2002).
Future direction for the management 
of CHF in Japan
CHF is a slowly progressive disease from stage A to stage D 
unless appropriately treated as described in the ACC/AHA 
guidelines (Hunt et al 2001). The strategy to manage CHF 
has been changing recently from treatment to prevention Vascular Health and Risk Management 2008:4(1) 111
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(Bansal et al 2006). Japanese CHF patients have several 
different proﬁ  les compared with Western CHF patients as 
follows; (a) the prevalence of CHF of ischemic origin is 
lower, (b) the percentage of elderly population is remarkably 
high, and (c) the penetration rate of evidence-based medi-
cine, such as ACEI/ARB or β-blockers, is not sufﬁ  ciently 
high yet. The current situation of the management of CHF 
in Japan is probably caused by the fact that the number of 
randomized treatment trials for Japanese patients is not 
enough yet. Given the expected future increase in Japanese 
patients with CHF, effective prevention strategy is necessary. 
Our on-going CHART-2 and SUPPORT studies will enable 
us to obtain effective strategies to improve the management 
of CHF in Japan.
Conclusions
The prevalence of CHF will rapidly increase in the next 
decades in many industrialized countries, including Japan. 
Large cohort studies with CHF patients are useful for risk 
stratiﬁ  cation and determination of preventive measures for 
the disorder. Large-scale, randomized treatment trials also are 
needed, especially in Japan, in order to obtain further evidence 
to improve the management of patients with CHF.
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